Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03254394 · ClinicalTrials.gov registry record · Phase 1
Lidocaine for Oxaliplatin-induced Neuropathy
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03254394 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 26 participants.
The verdict
NCT03254394, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen. Hypersensitivity to cold is the sensory hallmark of oxaliplatin-induced neuropathy, and it can predict the development of long-term neuropathy. In this study, the investigators aim to determine whether intravenous lidocaine can prevent oxaliplatin-induced cold hypersensitivity.
Interventions
- DRUG Placebo
- DRUG FOLFOX regimen
- DRUG Lidocaine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03254394
The ClinicalTrials.gov registry entry for NCT03254394 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03254394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03254394 about?
NCT03254394 is a clinical study titled "Lidocaine for Oxaliplatin-induced Neuropathy". Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen. Hypersensitivity to cold is the sensory hallmark of oxaliplatin-induced neuropathy, and it can predict the development of long-term neuropathy. In this...
What is the current status of trial NCT03254394?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-09-15. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT03254394?
The interventions under investigation include: Placebo (DRUG), FOLFOX regimen (DRUG), Lidocaine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03254394?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.